Abstract Number: 99 • 2019 ACR/ARP Annual Meeting
Mass Cytometry Immunophenotyping of Synovial Fluid from Checkpoint Inhibitor Related Arthritis
Background/Purpose: Anti-PD-1/PD-L1 checkpoint inhibitor therapies have produced remarkable results in stimulating immune responses against tumors. Checkpoint inhibitor therapy can also trigger a variety of autoimmune…Abstract Number: 1809 • 2019 ACR/ARP Annual Meeting
A Quarter of Patients Treated with Checkpoint Inhibitors Develop Immune-Related Adverse Events: A University Center Experience
Background/Purpose: Immune checkpoint inhibitors (ICIs) are increasingly becoming the mainstay of management of advanced malignancies, but can result in immune related adverse events (irAEs) affecting…Abstract Number: 150 • 2018 ACR/ARHP Annual Meeting
PD-1 Signaling Interferes with OX40L to Alter the Suppressive Function and Proliferation of CD4+ Regulatory T Cells in Lupus Mice
Background/Purpose: In systemic lupus erythematosus (SLE), the dysregulated production of autoantibodies is a consequence of disrupted T cell homeostasis. Programmed death-1 (PD-1), a negative regulator…Abstract Number: 351 • 2018 ACR/ARHP Annual Meeting
Rheumatic Immune-Related Adverse Events in Patients on ANTI-PD-1 Inhibitors: Fasciitis with Myositis Syndrome As a New Rheumatic Complication of Immunotherapy
Background/Purpose: To evaluate the prevalence and type of rheumatic immune-related adverse events (IRAEs) in patients receiving programmed cell death protein-1 (PD-1) inhibitors. Methods: This is…Abstract Number: 357 • 2018 ACR/ARHP Annual Meeting
Musculoskeletal Immune-Related Adverse Events with Use of Checkpoint Inhibitors in Malignancy: Experience in Sydney, Australia
Background/Purpose: The strategy of using monoclonal antibodies to inhibit checkpoints on T cells, and enhance T-cell activity against cancer cells has significantly improved the survival…Abstract Number: 361 • 2018 ACR/ARHP Annual Meeting
Risk Factors of Immune-Related Adverse Events in Patients Treated with Anti-Programmed Cell Death 1 Antibody Pembrolizumab
Background/Purpose: Immune checkpoint inhibitors have been established as a novel standard treatment for various types of malignancies. However, these new class of drugs have led…Abstract Number: 2459 • 2018 ACR/ARHP Annual Meeting
Nivolumab-Induced Synovial Tissue T Cell Infiltration, Sustained PD1 Occupancy and Resolution of Severe Synovitis with Infliximab Therapy
Background/Purpose: Checkpoint inhibitors (CI) for cancer therapy are associated with inflammation that can recapitulate features of autoimmunity, including synovitis resembling rheumatoid arthritis (RA). No reports…Abstract Number: 2797 • 2018 ACR/ARHP Annual Meeting
Regulation of Autoimmune T Cells By the Co-Receptors CD28 and PD-1
Background/Purpose: T cells play a major role in the pathogenesis of Rheumatoid Arthritis (RA). These cells are regulated by signals provided via the T cell…Abstract Number: 2095 • 2017 ACR/ARHP Annual Meeting
Traditional Disease Modifying Anti-Rheumatic Drugs (tDMARDs), Hydroxychloroquine (HCQ) and/or Sulfasalazine (SSZ), Are Rapidly Effective in Immune Checkpoint Inhibitors-Induced Inflammatory Arthritis
Background/Purpose: Immune checkpoint inhibitor (ICI) therapy is widely used in the treatment of metastatic melanoma and non-small cell lung cancer and it is under investigation…Abstract Number: 2580 • 2017 ACR/ARHP Annual Meeting
Exploiting Inhibition of PD1 Signaling in a Murine Model of Anti-SSA/Ro Associated Congenital Heart Block
Background/Purpose: The most serious manifestation of fetal exposure to maternal anti-Ro antibodies is the development of heart block. This work addresses the hypothesis that fetal…Abstract Number: 2705 • 2017 ACR/ARHP Annual Meeting
Aberrant Expression and Function of Human Circulating T Follicular Helper Cells and Its Subsets in IgG4 Related Disease
Background/Purpose: To study the expression and function of T follicular helper cells and its subsets in IgG4-related disease(IgG4-RD). Methods: Flow cytometry was performed to analyze…Abstract Number: 1340 • 2016 ACR/ARHP Annual Meeting
Type and Frequency of Immune-Related Adverse Reactions in Patients Treated with Pembrolizumab (Keytruda), a Monoclonal Antibody Directed Against PD-1, in Advanced Melanoma at a Single Institution
Background/Purpose: Although immune checkpoint inhibitors improve survival in patients with melanoma and other cancers, the alterations to the immune system induced by these medications can…Abstract Number: 2925 • 2016 ACR/ARHP Annual Meeting
Programmed Cell Death (PD)-1 May Play a Significant Role in the Pathogenesis of Rheumatoid Arthritis
Background/Purpose: PD-1 is a co-inhibitory transmembrane protein with a significant effect on immune regulation. Several studies have shown elevated expression levels of PD-1 on T…Abstract Number: 3042 • 2016 ACR/ARHP Annual Meeting
PD-1–Expressing T Cells in GCA Fail to Promote Immune Tolerance Functions
Background/Purpose: The vasculitic lesions in GCA are filled with differentiated effector T cells that sustain granuloma formation, vessel wall restructuring, neoangiogenesis and intimal hyperplasia. Persistent…Abstract Number: 2529 • 2015 ACR/ARHP Annual Meeting
Decreased Programmed Death Ligand-1 (PD-L1) in Systemic Lupus Erythematosus (SLE) Placenta
Background/Purpose: The increased rates of preeclampsia, preterm birth, and intrauterine growth restriction in SLE pregnancy are only partially explained by the vascular effects of anti-phospholipid…
ACR Meeting Abstracts